Injectable / Longevity, Cognitive & Immunity
PT-141 (Bremelanotide)
Melanocortin Agonist · 5mg
$59 USD per unit · Coming soon · 5mg / 2mL vial
FDA-approved melanocortin receptor agonist for sexual dysfunction. Activates MC3R and MC4R pathways for libido and arousal support.
Product information
PT-141 (Bremelanotide) is a synthetic peptide agonist of melanocortin receptors MC3R and MC4R, approved by the FDA for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike phosphodiesterase inhibitors that work peripherally on vascular tissue, PT-141 acts centrally in the hypothalamus to promote sexual desire and arousal through melanocortin pathway activation.
As a cyclic heptapeptide analog of alpha-MSH, PT-141 represents a novel mechanism for addressing sexual dysfunction, targeting the brain's sexual response systems rather than relying solely on peripheral blood flow. Clinical trials demonstrate significant improvements in desire, arousal, and sexual satisfaction metrics. The peptide's central mechanism makes it effective in both male and female applications, addressing desire-related dysfunction that vascular agents cannot.
Benefits
- Melanocortin MC3R/MC4R activation
- Central arousal pathway support
- FDA-recognized mechanism
- Non-vascular sexual function support
Specifications
- Fill / pack
- 5mg / 2mL vial
- Format
- Injectable
- Serving
- 1.75mg / dose
- Servings per container
- 2-3 doses
- Listed purity
- 99.5%
- Molecular weight / composition
- 1025.24 Da
- Storage
- Refrigerate 2-8°C
For laboratory and research use only. Not for human consumption.
Browse all peptide bioregulators or the Longevity, Cognitive & Immunity collection. All formulations.